Filing Details
- Accession Number:
- 0001104659-22-021506
- Form Type:
- 13G Filing
- Publication Date:
- 2022-02-13 19:00:00
- Filed By:
- Coucke Marc
- Company:
- Sophia Genetics Sa
- Filing Date:
- 2022-02-14
- SEC Url:
- 13G Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Marc Coucke | 0 | 6,993,800 | 0 | 6,993,800 | 6,993,800 | 11.0% |
| Alychlo N.V | 0 | 6,993,800 | 0 | 6,993,800 | 6,993,800 | 11.0% |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. __)*
SOPHiA GENETICS SA
(Name of Issuer)
Ordinary Shares, par value CHF 0.05 per share
(Title of Class of Securities)
H82027105
(CUSIP Number)
December 31, 2021
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
¨ Rule 13d-1(b)
¨ Rule 13d-1(c)
x Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. H82027105
| 1 | NAMES OF REPORTING PERSONS
Marc Coucke
|
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ¨
(b) x
|
| 3 | SEC USE ONLY
|
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
Belgium
|
| NUMBER
OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER
0
|
| 6 | SHARED VOTING POWER
6,993,800*
| |
| 7 | SOLE DISPOSITIVE POWER
0
| |
| 8 | SHARED DISPOSITIVE POWER
6,993,800*
|
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
6,993,800*
|
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
¨
|
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
11.0%**
|
| 12 | TYPE OF REPORTING PERSON
IN
|
* See Note on page 3.
** See Note on page 3.
2
CUSIP No. H82027105
| 1 | NAMES OF REPORTING PERSONS
Alychlo N.V.
|
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ¨
(b) x
|
| 3 | SEC USE ONLY |
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
Belgium
|
| NUMBER
OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER
0
|
| 6 | SHARED VOTING POWER
6,993,800*
| |
| 7 | SOLE DISPOSITIVE POWER
0
| |
| 8 | SHARED DISPOSITIVE POWER
6,993,800*
|
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
6,993,800*
|
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
☐
|
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
11.0%**
|
| 12 | TYPE OF REPORTING PERSON
CO
|
* Alychlo NV is the record holder of 6,993,800 ordinary shares of SOPHiA GENETICS SA. Marc Coucke is the principal shareholder, Chairman and Managing Director of Alychlo NV.
** According to publicly available information, the percentage ownership is calculated based on 63,857,604 ordinary shares issued and outstanding as of August 25, 2021, which is based on 63,338,111 ordinary shares the Issuer expected to be outstanding on or about July 27, 2021, as reported by the Issuer in its Prospectus filed pursuant to Rule 424(b)(4), Registration No. 333-257647, filed with the Securities and Exchange Commission (the “SEC”) on July 23, 2021 plus 519,493 ordinary shares issued and sold to the underwriters of its initial public offering pursuant to the underwriters’ option to purchase additional shares, as reported by the Issuer on Form 6-K filed on August 25, 2021.
3
CUSIP No. H82027105
| Item 1(a) | Name of Issuer:
SOPHiA GENETICS SA
|
| Item 1(b) | Address of Issuer's Principal Executive Offices:
Rue du Centre 172 CH-1025 Saint-Sulpice Switzerland
|
| Items 2(a) | Name of Persons Filing:
This Statement is filed on behalf of the following persons (collectively, the “Reporting Persons”): (i) Marc Coucke (ii) Alychlo NV
|
| Item 2(b) | Address of Principal Business Office:
The address of the principal business office of each Reporting Person is c/o Alychlo NV, Lembergsesteenweg 19, 9820 Merelbeke, Belgium
|
| Item 2(c) | Citizenship:
Marc Coucke is a citizen of Belgium Alychlo NV is a limited liability company organized under the laws of Belgium
|
| Item 2(d) | Title of Class of Securities:
Ordinary Shares, par value CHF 0.05 per share
|
| Item 2(e) | CUSIP Number:
H82027105
|
4
CUSIP No. H82027105
| Item 3 | If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is:
(a) ¨ Broker or dealer registered under Section 15 of the Act;
(b) ¨ Bank as defined in Section 3(a)(6) of the Act;
(c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
(d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
(e) ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
(f) ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii) (F);
(g) ¨ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii) (G);
(h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
(j) ¨ A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
(k) ¨ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
This Item 3 is not applicable. |
| Item 4 | Ownership:
The information required by Items 4(a)-(c), as of the date hereof, is set forth in Rows 5-11 of the cover page hereto for each Reporting Person and is incorporated herein by reference for each such Reporting Person.
|
| Item 5 | Ownership of Five Percent or Less of a Class:
Not applicable
|
| Item 6 | Ownership of More than Five Percent on Behalf of Another Person:
Not applicable
|
5
CUSIP No. H82027105
| Item 7 | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
Not applicable
|
| Item 8 | Identification and Classification of Members of the Group:
Not applicable
|
| Item 9 | Notice of Dissolution of Group:
Not applicable
|
| Item 10 | Certification:
Not applicable
|
6
CUSIP No. H82027105
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.
Dated: February 9, 2022
| By: | /s/ Marc Coucke | |
| Name: Marc Coucke | ||
| ALYCHLO NV | ||
| By: | /s/ Marc Coucke | |
| Name: Marc Coucke | ||
| Title: Chairman / Managing Director | ||
7
CUSIP No. H82027105
EXHIBIT 99.1
JOINT FILING AGREEMENT
The undersigned hereby agree that the statement on Schedule 13G with respect to the ordinary shares, par value CHF 0.05 per share, of SOPHiA GENETICS SA dated as of February 9, 2022 is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This joint filing agreement may be executed in any number of counterparts and all of such counterparts taken together shall constitute one and the same instrument.
Dated: February 9, 2022
| By: | /s/ Marc Coucke | |
| Name: Marc Coucke | ||
| ALYCHLO NV | ||
| By: | /s/ Marc Coucke | |
| Name: Marc Coucke | ||
| Title: Chairman / Managing Director | ||
8